GBB
AI Biomedical R&D Company
Hong Kong
November 7, 2024
Great Bay Bio ("GBB") and Suzhou Maga Technology Co., Ltd. ("Maga") have signed a strategic cooperation agreement, focusing on innovative drug development in multiple major disease areas. Through the integration of artificial intelligence and automation solutions, the two parties combine their strengths.Join hands to advance multiple key steps such as early biopharmaceutical research and upstream process development, providing innovative solutions for large molecule drugs and revolutionizing the acceleration of new drug development.
▲GBB Co-founderAndCEODr. Chen Liang and Dr. Zhang Yan, Co-founder and Chief Operating Officer of Suzhou Maga Technology Co., Ltd., Sign Strategic Cooperation Agreement
Dr. Liang Chen, co-founder and CEO of Great Bay Bio, stated:"Maga is committed to the deep integration of technologies such as robotics, automation, and artificial intelligence with industry applications, empowering innovation breakthroughs and digital transformation across numerous fields. It has already demonstrated extraordinary innovation in life sciences and new drug development. Through this strategic cooperation, GBB will leverage Maga's advanced productivity tools and services to further strengthen its own complete closed-loop intelligent biopharmaceutical development ecosystem, making drug research and development smarter and drug production automated. It will continuously provide strong momentum for drug discovery and CMC development, reduce costs and improve efficiency, and help customers develop products faster and better."
▲GBB Co-Founder& CEODr. Chen Liang
Dr. Yan Zhang, Co-founder and Chief Operating Officer of Suzhou Maga Technology Co., Ltd., stated:“"We are very pleased to partner with Great Bay Bio in the challenging and promising field of antibody drugs for in-depth cooperation. Maga has always adhered to the vision of ‘empowering industry innovation breakthroughs and digital transformation with advanced productive tools,’ and is committed to applying cutting-edge technologies such as AI and automation to the core processes of drug development. We believe that through our joint efforts, we can break the bottleneck of traditional R&D models, accelerate the process of biologics from the lab to the market, and contribute to human health and well-being."
▲Dr. Zhang Yan, Co-founder and Chief Operating Officer of Suzhou Maga Technology Co., Ltd.
GBB was founded in 2019 in the Guangdong-Hong Kong-Macao Greater Bay Area, with its headquarters located in the Hong Kong Science Park. Guided by the corporate vision of "making global bioprocess development simpler and more efficient," GBB is committed to applying artificial intelligence platforms to drive bioprocess technological innovation, addressing various pain points in drug development such as long cycles, high costs, and low success rates, with the long-term goal of enhancing human health and value.
Maga Technology was founded in 2016 and is a technology company dedicated to providing advanced productivity tools. It aims to empower innovation breakthroughs and digital transformation in fields such as life sciences, new drug development, clinical diagnostics, applied chemistry, and advanced manufacturing through the deep integration of robotics, automation, artificial intelligence, and industry applications, creating a more efficient, healthier, and better world for everyone.
In the field of life sciences, Maga continuously develops innovative, high-quality intelligent automation products to provide customers with diversified, full-process solutions. It has currently achieved full-chain coverage from the R&D end, production end to downstream testing laboratories, supporting the exploration and development of life science research. Combined with the research capabilities of its self-developed general-purpose intelligent biolab — Maga Kunpeng Lab — it brings high value-added productivity tools and services to the industry, accelerating intelligent automation transformation in areas such as new drug development, cell and gene therapy, organoids, and synthetic biology, improving human life and health.
END
Great Bay Bio and MEGAROBO Forge Strategic Partnership
Hong Kong
November 7, 2024
Great Bay Bio (hereinafter referred to as “GBB”) and Beijing MEGAROBO Co., Ltd. (hereinafter referred to as “MEGAROBO”) signed a strategic cooperation agreement, focusing on innovative drug development in multiple major disease areas. By combining strengths, the two parties will integrate AI and automation solutions to advance critical steps in early-stage biopharmaceutical research and upstream process development. This collaboration aims to provide innovative solutions for large-molecule drugs, revolutionizing and accelerating the drug development processes.
Dr. Michael Chen, Co-founder and CEO of Great Bay Bio, and Dr. Yan Zhang, Co-founder and COO of MEGAROBO, signed the strategic cooperation agreement
Dr. Michael Chen, Co-founder and CEO of Great Bay Bio, stated: "MEGAROBO is committed to empowering innovation and digital transformation across various fields through the deep integration of robotics, automation, and AI with industry applications. MEGAROBO has already demonstrated outstanding innovation in life sciences, new drug development, and other areas. Through this strategic partnership, Great Bay Bio will leverage MEGAROBO's advanced productivity tools and services to further enhance intelligent biopharmaceutical development ecosystem, achieving a closed loop. This will enable intelligent drug discovery, automated drug production, and continuous support for drug discovery and CMC development, leading to cost reduction, efficiency improvement, and faster, better product development for clients."
Dr. Michael Chen, Co-founder and CEO of Great Bay Bio
Dr. Yan Zhang, Co-founder and COO of MEGAROBO, stated: “We are pleased to partner with Great Bay Bio to embark on deep collaboration in the field of antibody drugs, which is full of challenges and opportunities. MEGAROBO has always adhered to the vision of 'Empowering Digital Transformation with Advanced Production Tools to Make the World Healthier and Better' and is committed to applying cutting-edge technologies such as AI and automation to the core drug development processes. We believe that through our joint efforts, we can break the bottlenecks of traditional R&D models, accelerate the progress of biologics from the lab to the market, and contribute to the health and well-being of humanity."
Dr. Yan Zhang, Co-founder and COO of MEGAROBO
Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Global Bioprocessing Made Simpler and More Efficient. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States.
Founded in 2016, MEGAROBO is a science and technology company specializing in providing advanced production tools for life sciences, new drug discovery, clinical diagnostics, applied chemistry, and advanced manufacturing industries. MEGAROBO is dedicated to leveraging robotic automation and AI technologies to empower innovation breakthroughs and digital transformation, to engineer a more efficient, healthier, and better world.
MEGAROBO provides innovative intelligent automation products and solutions of high quality for the life sciences industry, covering R&D, production, and detection. With the research capabilities of MegaLab, the self-developed intelligent biological laboratory, MEGAROBO provides high-value productivity tools and services, accelerating the intelligent automation revolution in new drug discovery, cell and gene therapy, organoids, and synthetic biology, ultimately improving human health.
END